tiprankstipranks
Magenta Therapeutics Inc (MGTA)
NASDAQ:MGTA

Magenta Therapeutics Stock Analysis & Ratings

MGTA Stock Chart & Stats

Day’s Range$1.14 - $1.25
52-Week Range$0.92 - $12.98
Previous Close$1.1
Volume219.57K
Average Volume (3M)314.16K
Market Cap$69.38M
P/E Ratio-0.8
Beta2.22
Next EarningsAug 11, 2022
EPS ForecastN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score6
EPS (TTM)-1.30


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

MGTA FAQ

What was Magenta Therapeutics’s price range in the past 12 months?
Magenta Therapeutics lowest stock price was $0.92 and its highest was $12.98 in the past 12 months.
    What is Magenta Therapeutics’s market cap?
    Magenta Therapeutics’s market cap is $69.38M.
      What is Magenta Therapeutics’s price target?
      The average price target for Magenta Therapeutics is $5.67. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $8.00 ,the lowest forecast is $3.00. The average price target represents 380.51% Increase from the current price of $1.18.
        What do analysts say about Magenta Therapeutics?
        Magenta Therapeutics’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.
          When is Magenta Therapeutics’s upcoming earnings report date?
          Magenta Therapeutics’s upcoming earnings report date is Aug 11, 2022 which is in 85 days.
            How were Magenta Therapeutics’s earnings last quarter?
            Magenta Therapeutics released its earnings results on May 16, 2022. The company reported -$0.39 earnings per share for the quarter, missing the consensus estimate of -$0.312 by -$0.078.
              Is Magenta Therapeutics overvalued?
              According to Wall Street analysts Magenta Therapeutics’s price is currently Undervalued.
                Does Magenta Therapeutics pay dividends?
                Magenta Therapeutics does not currently pay dividends.
                What is Magenta Therapeutics’s EPS estimate?
                Magenta Therapeutics’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Magenta Therapeutics have?
                Magenta Therapeutics has 58,800,000 shares outstanding.
                  What happened to Magenta Therapeutics’s price movement after its last earnings report?
                  Magenta Therapeutics reported an EPS of -$0.39 in its last earnings report, missing expectations of -$0.312. Following the earnings report the stock price went down -3.509%.
                    Which hedge fund is a major shareholder of Magenta Therapeutics?
                    Among the largest hedge funds holding Magenta Therapeutics’s share is Platinum Investment Management. It holds Magenta Therapeutics’s shares valued at 930K.

                      ---

                      Magenta Therapeutics Stock Analysis

                      The Magenta Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Magenta Therapeutics Inc

                      Magenta Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of novel medicines for bone marrow transplants. It offers platform that focuses on critical areas of transplant medicine. The company was founded by David Scadden, Derrick Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner in June 2015 and is headquartered in Cambridge, MA.

                      ---
                      Similar Stocks
                      Company
                      Price & Change
                      Follow
                      Avrobio
                      Meiragtx Holdings
                      Rubius Therapeutics
                      Tricida

                      Popular Stocks

                      ---
                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis